ReviewNatural products and bioprospecting2026
A review on natural enzyme inhibitors: an effective approach to control postprandial hyperglycemia in type II diabetes.
Review in Natural products and bioprospecting, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimization and Metabolomic Profiling ofInternational journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type II diabetes (T2D) is a chronic disease caused by hyperglycemia, insulin resistance, and insufficient insulin production. Inhibition of α-amylase, α-glucosidase, and dipeptidyl peptidase (DPP-IV) enzymes is considered a crucial interventional approach in managing T2D. Therefore, identification of natural enzyme inhibitors is essential. Hence, this study aims to highlight existing gaps and future needs regarding the potential application of natural inhibitors such as carbohydrates, lipid compounds, phytochemicals, probiotic strains, and bioactive peptides in the inhibition of enzymes involved in T2D as well as their inhibitory effects which were reviewed completely. The results of most studies showed that phenolic compounds and polysaccharides impart significant biological potential in inhibiting enzymes. This review highlights that food products fermented by probiotics possess considerable potential for diabetes control. Peptides, liposoluble, and phytochemical compounds play an obvious role in diabetes management, promising results from enzyme inhibition assays suggesting their potential as safer alternatives to conventional treatments for diabetes. However, several limitations such as type of assay methods, enzyme sources, bioavailability, and lack of research resources were observed. Therefore, additional studies should be carried out to establish optimal dosages, bioavailability, and validation methods. Understanding the inhibitory mechanisms of natural enzyme inhibitors and examining the structure-activity relationships between them are critical subjects that must receive more attention in future researches. Additionally, it is important to address the gap between scientific research and the commercialization of natural products. Hence, future efforts should prioritize conducting cell-based studies and clinical trials to evaluate the efficacy and safety of these products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.